Curemark

About:

Curemark is a socially-driven biotechnology company focusing on the treatment of autism and other neurological diseases.

Website: http://www.curemark.com

Twitter/X: Curemark

Description:

Curemark is a biopharmaceutical company that focuses on the development of novel therapies to treat serious diseases for which there are limited treatment options for patients in need. Their pipeline includes two Phase III clinical-stage programs for Autism and ADHD as well as three preclinical programs directed at Parkinson’s Disease, Schizophrenia, and Addiction. All of their product candidates address severe neurologic diseases that are currently believed to be underserved by available approved therapies and represent large potential commercial market opportunities. They believe that their product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies.

Total Funding Amount:

$74.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Rye, New York, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)curemark.com

Founders:

Joan Fallon

Number of Employees:

11-50

Last Funding Date:

2021-04-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai